George Psevdos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
George Psevdos has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Victoria Sharp
‡Center for Comprehensive Care, St. Luke's-Roosevelt Medical Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
6 shared publicationsJong Hun Kim
Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA
3 shared publicationsEfrain Gonzalez
From the *Department of Infectious Diseases, St Luke's Roosevelt Medical Center (an affiliate of Columbia University College of Physicians and Surgeons) and †Center for Comprehensive Care, New York, NY
2 shared publicationsJin Suh
2 shared publicationsA Paniz-Mondolfi
Department of Pathology, St Luke's Roosevelt Hospital, New York, NY, USA
1 shared publicationC Batog
Department of Medicine, St Luke's Roosevelt Hospital, New York, NY, USA
1 shared publication
Latest Publications
- 21 December 2012
- Published by Springer Nature in Infection
- Vol. 41 (2) , 545-551
All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART)
The overall mortality rate among human immunodeficiency virus (HIV)-infected patients has significantly declined in the era of highly active antiretroviral therapy (HAART). However, little is known about the causes of death for HIV-infected patients who are hospitalized in acute care hospitals.
- 21 December 2012
- Published by Springer Nature in Infection
- Vol. 41 (2) , 545-551
All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART)
The overall mortality rate among human immunodeficiency virus (HIV)-infected patients has significantly declined in the era of highly active antiretroviral therapy (HAART). However, little is known about the causes of death for HIV-infected patients who are hospitalized in acute care hospitals.
- Open Access
- 30 January 2012
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 6 (1) , 86-91
Persistence of Protective Hepatitis B Surface Antibody Titers after Successful Double-Dose Hepatitis B Virus Rescue Vaccination in HIVInfected Patients
To assess the durability of protective hepatitis B surface antibody (anti-HBs) titers in HIV-infected patients who responded to double-dose hepatitis B virus (HBV) rescue vaccination. A retrospective chart review was performed for HIV-infected patients who received the double-dose HBV rescue vaccination at 0-, 1-, and 2-month intervals after they had failed conventional HBV vaccination series. A protective antibody response was defined as an anti-HBs titer ≥10 mIU/mL. Of 54 HIV-infected patients who received a double-dose HBV rescue vaccination, 44 patients (81.5%) had a positive response and achieved protective anti-HB titers. Of the 44 patients who developed protective anti-HB titers, 33 patients received an evaluation of their anti-HB titers 12 months later. Of the 33 patients, 19 (57.6%) had persistent protective anti-HB titers (persistent responders, PR), and 14 patients (42.4%) lost their protective anti-HB titers (nonpersistent responders, NPR). There were significantly more patients who had an undetectable HIV viral load (<50 copies/mL) at baseline and follow-up in the PR group (11/19, 57.9%) than in the NPR group (3/14, 21.4%, p=0.036). Logistic regression analysis showed that an undetectable HIV viral load at baseline and follow-up (odds ratio, 12.973; 95% confidence interval, 1.189 to 141.515; p=0.036) was associated with PR. Protective anti-HB titers may decrease over time after successful double-dose HBV rescue vaccination in HIV-infected patients. HIV viral load suppression could improve the persistence of anti-HB titers.
- 30 January 2012
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 6 (1) , 86-91
Open AccessPersistence of Protective Hepatitis B Surface Antibody Titers after Successful Double-Dose Hepatitis B Virus Rescue Vaccination in HIVInfected Patients
To assess the durability of protective hepatitis B surface antibody (anti-HBs) titers in HIV-infected patients who responded to double-dose hepatitis B virus (HBV) rescue vaccination. A retrospective chart review was performed for HIV-infected patients who received the double-dose HBV rescue vaccination at 0-, 1-, and 2-month intervals after they had failed conventional HBV vaccination series. A protective antibody response was defined as an anti-HBs titer ≥10 mIU/mL. Of 54 HIV-infected patients who received a double-dose HBV rescue vaccination, 44 patients (81.5%) had a positive response and achieved protective anti-HB titers. Of the 44 patients who developed protective anti-HB titers, 33 patients received an evaluation of their anti-HB titers 12 months later. Of the 33 patients, 19 (57.6%) had persistent protective anti-HB titers (persistent responders, PR), and 14 patients (42.4%) lost their protective anti-HB titers (nonpersistent responders, NPR). There were significantly more patients who had an undetectable HIV viral load (<50 copies/mL) at baseline and follow-up in the PR group (11/19, 57.9%) than in the NPR group (3/14, 21.4%, p=0.036). Logistic regression analysis showed that an undetectable HIV viral load at baseline and follow-up (odds ratio, 12.973; 95% confidence interval, 1.189 to 141.515; p=0.036) was associated with PR. Protective anti-HB titers may decrease over time after successful double-dose HBV rescue vaccination in HIV-infected patients. HIV viral load suppression could improve the persistence of anti-HB titers.
- Open Access
- 1 January 2012
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 27 (7) , 830-833
Five-Year Review of HIV-Hepatitis B Virus (HBV) Co-Infected Patients in a New York City AIDS Center
Kim JH, et al. J Korean Med Sci. 2012 Jul;27(7):830-833. http://dx.doi.org/10.3346/jkms.2012.27.7.830
- 1 January 2012
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 27 (7) , 830-833
Open AccessFive-Year Review of HIV-Hepatitis B Virus (HBV) Co-Infected Patients in a New York City AIDS Center
Kim JH, et al. J Korean Med Sci. 2012 Jul;27(7):830-833. http://dx.doi.org/10.3346/jkms.2012.27.7.830
- 1 September 2011
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 19 (5) , 340-342
Clinical Presentation of 2009 H1N1 Influenza A Disease in HIV-Infected Patients
Background: H1N1-novel Influenza A seemed to take the United States by surprise in the summer of 2009, and it soon reached epidemic proportions, affecting large and varied sections of the population. Immune-compromised patient populations, including human immunodeficiency virus (HIV)-infected individuals, were thought to be at higher risk. The study examined the severity and characteristics of H1N1 Influenza disease in HIV-infected patients and assessed treatment outcomes. Methods: Retrospective chart review of 2951 HIV-infected patients from May 1, 2009 to December 31, 2009. Results: Ninety-four patients presented with flulike symptoms, and 25 patients tested positive by culture for H1N1. Only 4 of 25 rapid test results were positive. The mean age was 46 years. Ninety-two percent were on antiretroviral therapy, and 56% were men. The mean CD4+ T-cell count was 496/μL, and viral load was undetectable in 60% of the patients. Ten patients required hospitalization, and 3 received mechanical ventilation. One patient died. Twenty-four patients received osetalmivir, and one patient recovered without treatment. There was no difference between the hospitalized and nonhospitalized patients in the CD4+ T-cell count (P = 0.8462) and viral load (P = 0.5849). Hospitalized patients were older (mean age, 54.3 vs. 41.5 years, P = 0.001), and logistic regression analysis showed that age older than 46 years (OR = 18.000; 95% confidence interval, 1.75-184.68, P = 0.032) was associated with hospitalization. Conclusions: H1N1 influenza was a rare occurrence in our population. Most of the patients recovered. Older patients were more likely to get hospitalized.
- 1 September 2011
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 19 (5) , 340-342
Clinical Presentation of 2009 H1N1 Influenza A Disease in HIV-Infected Patients
Background: H1N1-novel Influenza A seemed to take the United States by surprise in the summer of 2009, and it soon reached epidemic proportions, affecting large and varied sections of the population. Immune-compromised patient populations, including human immunodeficiency virus (HIV)-infected individuals, were thought to be at higher risk. The study examined the severity and characteristics of H1N1 Influenza disease in HIV-infected patients and assessed treatment outcomes. Methods: Retrospective chart review of 2951 HIV-infected patients from May 1, 2009 to December 31, 2009. Results: Ninety-four patients presented with flulike symptoms, and 25 patients tested positive by culture for H1N1. Only 4 of 25 rapid test results were positive. The mean age was 46 years. Ninety-two percent were on antiretroviral therapy, and 56% were men. The mean CD4+ T-cell count was 496/μL, and viral load was undetectable in 60% of the patients. Ten patients required hospitalization, and 3 received mechanical ventilation. One patient died. Twenty-four patients received osetalmivir, and one patient recovered without treatment. There was no difference between the hospitalized and nonhospitalized patients in the CD4+ T-cell count (P = 0.8462) and viral load (P = 0.5849). Hospitalized patients were older (mean age, 54.3 vs. 41.5 years, P = 0.001), and logistic regression analysis showed that age older than 46 years (OR = 18.000; 95% confidence interval, 1.75-184.68, P = 0.032) was associated with hospitalization. Conclusions: H1N1 influenza was a rare occurrence in our population. Most of the patients recovered. Older patients were more likely to get hospitalized.
- 1 July 2011
- Vol. 124 (14) , 2123-6
Factors influencing syphilis treatment failure and/or re-infection in HIV co-infected patients: immunosuppression or behaviors.
Recent studies have reported overall increasing rates of syphilis with a high rate of human immunodeficiency virus (HIV) co-infection. However, there is little information about factors influencing syphilis treatment failure and/or re-infection in HIV co-infected patients. We conducted a study to evaluate factors associated with syphilis treatment failure/re-infection in HIV co-infected patients. We reviewed 3542 medical records of HIV-infected patients from January 2005 to December 2007 followed up at HIV Clinic in New York City. Patients were categorized by rapid plasma regain titer (RPR) into success/serofast (4-fold decrease in RPR by 12 months after treatment, RPR conversion to nonreactive, persistently stable reactive RPR with no 4-fold increase), and failure/re-infection (failure to decrease 4 folds in RPR by 12 months after treatment, 4-fold increase in RPR from baseline). Among a total of 156 patients who met the eligibility criteria, 122 (78.2%) were under success/serofast category, and 34 (21.8%) were under failure/re-infection category. HIV viral load, CD4 cell count, and use of highly active antiretroviral therapy (HAART) were not associated with syphilis treatment failure/re-infection. However, early syphilis stage (OR: 11.036, 95%CI: 2.499 - 48.740, P = 0.002) and high (> 1:64) RPR titers (OR: 715.921, 95%CI: 422.175 - 23 113.396, P < 0.001) were significantly associated. No correlations were seen with depressed immune states with syphilis treatment failure and/or re-infection. However, association with early stage syphilis suggests that risky psychological sexual behaviors may be the most important leading factor, emphasizing needs for safe sex education.
- 1 July 2011
- Vol. 124 (14) , 2123-6
Factors influencing syphilis treatment failure and/or re-infection in HIV co-infected patients: immunosuppression or behaviors.
Recent studies have reported overall increasing rates of syphilis with a high rate of human immunodeficiency virus (HIV) co-infection. However, there is little information about factors influencing syphilis treatment failure and/or re-infection in HIV co-infected patients. We conducted a study to evaluate factors associated with syphilis treatment failure/re-infection in HIV co-infected patients. We reviewed 3542 medical records of HIV-infected patients from January 2005 to December 2007 followed up at HIV Clinic in New York City. Patients were categorized by rapid plasma regain titer (RPR) into success/serofast (4-fold decrease in RPR by 12 months after treatment, RPR conversion to nonreactive, persistently stable reactive RPR with no 4-fold increase), and failure/re-infection (failure to decrease 4 folds in RPR by 12 months after treatment, 4-fold increase in RPR from baseline). Among a total of 156 patients who met the eligibility criteria, 122 (78.2%) were under success/serofast category, and 34 (21.8%) were under failure/re-infection category. HIV viral load, CD4 cell count, and use of highly active antiretroviral therapy (HAART) were not associated with syphilis treatment failure/re-infection. However, early syphilis stage (OR: 11.036, 95%CI: 2.499 - 48.740, P = 0.002) and high (> 1:64) RPR titers (OR: 715.921, 95%CI: 422.175 - 23 113.396, P < 0.001) were significantly associated. No correlations were seen with depressed immune states with syphilis treatment failure and/or re-infection. However, association with early stage syphilis suggests that risky psychological sexual behaviors may be the most important leading factor, emphasizing needs for safe sex education.
- Open Access
- 27 May 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 209
Epstein-Barr virus myelitis and Castleman's disease in a patient with acquired immune deficiency syndrome: a case report
Few cases of Epstein-Barr virus myelitis have been described in the literature. Multi-centric Castleman's disease is a lymphoproliferative disorder that is well known for its associations with the human immunodeficiency virus, human herpes virus 8, and Kaposi's sarcoma. The concurrent presentation of these two diseases in a patient at the same time is extremely unusual.
- 27 May 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 209
Open AccessEpstein-Barr virus myelitis and Castleman's disease in a patient with acquired immune deficiency syndrome: a case report
Few cases of Epstein-Barr virus myelitis have been described in the literature. Multi-centric Castleman's disease is a lymphoproliferative disorder that is well known for its associations with the human immunodeficiency virus, human herpes virus 8, and Kaposi's sarcoma. The concurrent presentation of these two diseases in a patient at the same time is extremely unusual.
- 1 May 2011
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 19 (3) , 226-228
Atazanavir-Associated QT Interval Prolongation and Torsades de Points in a Patient With Liver Cirrhosis
- 1 May 2011
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 19 (3) , 226-228
Atazanavir-Associated QT Interval Prolongation and Torsades de Points in a Patient With Liver Cirrhosis
- 1 December 2010
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 21 (12) , 842-844
Eosinophilic oesophagitis: an unsuspected aetiology for dysphagia in an HIV-positive patient
Patients with HIV/AIDS are often afflicted with oesophageal disorders. Opportunistic infections such as candidiasis, herpes simplex, cytomegalovirus, mycobacterial infections, Kaposi sarcoma or lymphoma involving the oesophagus, motility disorders and reflux oesophagitis are the usual culprits. Eosinophilic oesophagitis (EE), a recently recognized entity, is an important cause of dysphagia, food impaction and chest discomfort. We report the case of an HIV-infected man who had persistent dysphagia for six months despite treatment with proton pump inhibitor. He was diagnosed with EE after having endoscopic evaluation and biopsy of his oesophagus and was successfully treated with swallowed fluticasone. This case represents the first reported case of EE in an HIV-infected individual.
- 1 December 2010
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 21 (12) , 842-844
Eosinophilic oesophagitis: an unsuspected aetiology for dysphagia in an HIV-positive patient
Patients with HIV/AIDS are often afflicted with oesophageal disorders. Opportunistic infections such as candidiasis, herpes simplex, cytomegalovirus, mycobacterial infections, Kaposi sarcoma or lymphoma involving the oesophagus, motility disorders and reflux oesophagitis are the usual culprits. Eosinophilic oesophagitis (EE), a recently recognized entity, is an important cause of dysphagia, food impaction and chest discomfort. We report the case of an HIV-infected man who had persistent dysphagia for six months despite treatment with proton pump inhibitor. He was diagnosed with EE after having endoscopic evaluation and biopsy of his oesophagus and was successfully treated with swallowed fluticasone. This case represents the first reported case of EE in an HIV-infected individual.
- Open Access
- 1 January 2010
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 21 (3) , e109-e110
Successful treatment of uncomplicated gonococcal urethritis in HIV-infected patients with single-dose oral cefpodoxime
Fluoroquinolones are no longer recommended for the treatment of gonococcal infections in the United States. Cephalosporins – ceftriaxone and cefixime – are the treatment of choice, as suggested by the Centers for Disease Control and Prevention (USA). There are limited data on the efficacy of cefpodoxime for the treatment of uncomplicated gonococcal infections. Two cases of HIV-infected homosexual men who were successfully treated with cefpodoxime for urethritis caused byNeisseria gonorrhoeaeare described in the present study.
- 1 January 2010
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 21 (3) , e109-e110
Open AccessSuccessful treatment of uncomplicated gonococcal urethritis in HIV-infected patients with single-dose oral cefpodoxime
Fluoroquinolones are no longer recommended for the treatment of gonococcal infections in the United States. Cephalosporins – ceftriaxone and cefixime – are the treatment of choice, as suggested by the Centers for Disease Control and Prevention (USA). There are limited data on the efficacy of cefpodoxime for the treatment of uncomplicated gonococcal infections. Two cases of HIV-infected homosexual men who were successfully treated with cefpodoxime for urethritis caused byNeisseria gonorrhoeaeare described in the present study.
- 1 August 2009
- Vol. 19 (6) , 245-8
Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen. Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule. Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent. Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.
- 1 August 2009
- Vol. 19 (6) , 245-8
Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen. Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule. Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent. Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.